Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer

The combination of pertuzumab and trastuzumab resulted in a clinical benefit rate (CBR) of 50% in patients with human epidermal growth factor receptor 2 (HER2) -positive breast cancer whose disease progressed during prior trastuzumab-based therapy. To define whether this previously observed encourag...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Journal of clinical oncology Ročník 30; číslo 14; s. 1594
Hlavní autori:	Cortés, Javier, Fumoleau, Pierre, Bianchi, Giulia Valeria, Petrella, Teresa M, Gelmon, Karen, Pivot, Xavier, Verma, Shailendra, Albanell, Joan, Conte, Pierfranco, Lluch, Ana, Salvagni, Stefania, Servent, Veronique, Gianni, Luca, Scaltriti, Maurizio, Ross, Graham A, Dixon, Joanna, Szado, Tania, Baselga, José
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States 10.05.2012
Predmet:	Adult Age Factors Aged Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Breast Neoplasms - drug therapy Breast Neoplasms - metabolism Breast Neoplasms - mortality Breast Neoplasms - pathology Disease Progression Disease-Free Survival Dose-Response Relationship, Drug Drug Administration Schedule Female Humans Maximum Tolerated Dose Middle Aged Neoplasm Invasiveness - pathology Neoplasm Staging Patient Selection Prognosis Prospective Studies Receptor, ErbB-2 - metabolism Risk Assessment Survival Analysis Trastuzumab Treatment Outcome
ISSN:	1527-7755, 1527-7755
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!